Fiche publication
Date publication
septembre 2022
Journal
Annales pharmaceutiques francaises
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PRETET Jean-Luc
Tous les auteurs :
Baraquin A, Pépin L, Floerchinger P, Lepiller Q, Prétet JL
Lien Pubmed
Résumé
In France, recent advances in cervical cancer screening include an organized cervical cancer-screening program and the introduction of HPV testing as a first-line test for women aged 30-65 years. The HPV test, performed on a cervical smear taken by a health professional, could also be performed on a vaginal self-sample in certain indications. The detection kits used to test for HPV should target high-risk HPV, be validated for screening and meet the performance requirements for this indication. Although no longer used as a first-line test in women aged 30-65 years, cytological examination of cervical cells remains important, particularly in the triage of HPV positive women. The interest of other biological techniques, such as HPV genotyping, viral load, cellular expression of p16/Ki-67 proteins and the methylation of cellular or viral genes, still needs to be clarified, but they could help to refine the triage strategy of HPV-positive women and limit the need for colposcopy and unnecessary stress for patients.
Mots clés
Cervix, Col de l’utérus, HPV test, cancer prevention, dépistage organisé, organized screening, prévention des cancers, test HPV
Référence
Ann Pharm Fr. 2022 09 20;:
